0001209191-19-050922.txt : 20190926 0001209191-19-050922.hdr.sgml : 20190926 20190926211727 ACCESSION NUMBER: 0001209191-19-050922 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190924 FILED AS OF DATE: 20190926 DATE AS OF CHANGE: 20190926 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Levine James E. CENTRAL INDEX KEY: 0001463151 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36912 FILM NUMBER: 191119443 MAIL ADDRESS: STREET 1: 55 CAMBRIDGE PARKWAY STREET 2: 8TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cidara Therapeutics, Inc. CENTRAL INDEX KEY: 0001610618 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 461537286 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE STREET 2: SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-752-6170 MAIL ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE STREET 2: SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: K2 THERAPEUTICS, INC. DATE OF NAME CHANGE: 20140611 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-09-24 0 0001610618 Cidara Therapeutics, Inc. CDTX 0001463151 Levine James E. C/O CIDARA THERAPEUTICS, INC. 6310 NANCY RIDGE DR #101 SAN DIEGO CA 92121 0 1 0 0 Chief Financial Officer Common Stock 2019-09-24 4 P 0 30000 1.908 A 205000 D The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.90 to $1.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. /s/ Jessica Oien, Attorney-in-fact 2019-09-26